Evidence map›Paper›PMID 39162189›Full record

Observational studySkin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI)2024

Improvement of self-administration experience with a new injection device: Real-life experience with risankizumab in patients with psoriasis.

Alexandra Maria Giovanna Brunasso, Ilaria Salvi, Stefania Sorbara, Andrea Muracchioli, Elena De Col, Manuela Baldari, Aurora Parodi, Emanuele Cozzani, Martina Burlando

Abstract readMulticenter StudyObservational Study
In one paragraph

Observational study in Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Improvement of self-administration experience with a new injection device: Real-life experience with risankizumab in patients with psoriasis.Skin research and technology : official journal of International Society for Bioengineering and the Skin (ISBS) [and] International Society for Digital Imaging of Skin (ISDIS) [and] International Society for Skin Imaging (ISSI) · 2024
    Observational
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Alexandra Maria Giovanna BrunassoUnit of Dermatology, Villa Scassi Hospital, ASL3, Genoa, Italy.
Ilaria SalviSection of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy.
Stefania SorbaraDivision of Dermatology, EO Galliera, Genoa, Italy.
Andrea MuracchioliUnit of Dermatology, San Bartolomeo Hospital, La Spezia, Italy.
Elena De ColUnit of Dermatology, Civil Hospital of Imperia, Imperia, Italy.
Manuela BaldariUnit of Dermatology, Civil Hospital of Sestri Levante, Sestri Levante, Genoa, Italy.
Aurora ParodiSection of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy.
Emanuele CozzaniSection of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy.
Martina BurlandoSection of Dermatology, Department of Health Sciences (DiSSal), University of Genoa, Genoa, Italy.ORCID https://orcid.org/0000-0002-4381-6718

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundTrypanophobia or "needle phobia" represents a potential hindrance to the effective management of chronic diseases whenever an injectable therapy might be required, especially in case of frequent administrations. Psoriasis, a chronic dermatologic disease, can be effectively treated with biologic drugs administered subcutaneously. Thankfully, anti-IL-23 drugs require few administrations per year and are available in prefilled pens that hide the needle, thus representing a convenient option in patients with trypanophobia.

methodsAn observational multicentric study was conducted on patients with moderate-to-severe psoriasis who were treated with 75 mg × 2 risankizumab prefilled syringe therapy for more than 6 months and reported a loss of efficacy measured by the Psoriasis Area and Severity Index (PASI) from PASI 90 to PASI 75 attributed to a reduction of adherence due to trypanophobia. The patients were switched to 1 prefilled pen of risankizumab 150 mg and asked to fill out the Self-Injection Assessment Questionnaire (SIAQ) before and after the injection at week 0 and at the following administration after 12 weeks. Subjects scored each item of the SIAQ on a 5-point scale, scores were later transformed from 0 (worst experience) to 10 (best experience).

resultsTwenty-two patients were enrolled. The mean SIAQ predose domain scores were 5.5 for feelings about injection, 6.2 for self-confidence, and 6.4 for satisfaction with self-injection. After dose scores were higher (> 8.5) for each of the six domains at Week 0 and even higher after 12 weeks (> 9.0).

conclusionsUser-friendly devices, such as prefilled pens, and a lower number of injections improved patient satisfaction in a group of patients with psoriasis on treatment with biologic drugs. We believe that treatment adherence could be positively influenced by such changes in the way of administration of a biologic treatment.

Indexed as

PsoriasisSelf AdministrationAdultAgedAntibodies, MonoclonalFemaleHumansInjections, SubcutaneousMaleMiddle AgedPatient SatisfactionSeverity of Illness IndexSurveys and QuestionnairesSyringesTreatment OutcomeAntibodies, Monoclonalrisankizumabbiologic treatmentdermatologyneedle phobiapsoriasisrisankizumabtrypanophobia

Identifiers

PMID39162189
PMCPMC11333944

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.